These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 2189148)

  • 1. Rational management of the 'on-off' syndrome in Parkinson's disease.
    Coleman RJ
    Q J Med; 1990 Feb; 74(274):121-31. PubMed ID: 2189148
    [No Abstract]   [Full Text] [Related]  

  • 2. Levodopa effect upon functional balance of Parkinson's disease patients.
    Nova IC; Perracini MR; Ferraz HB
    Parkinsonism Relat Disord; 2004 Oct; 10(7):411-5. PubMed ID: 15465397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of levodopa-responsive camptocormia associated with advanced Parkinson's disease.
    Ho B; Prakash R; Morgan JC; Sethi KD
    Nat Clin Pract Neurol; 2007 Sep; 3(9):526-30. PubMed ID: 17805247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary functions in Parkinson's disease.
    Sathyaprabha TN; Kapavarapu PK; Pall PK; Thennarasu K; Raju TR
    Indian J Chest Dis Allied Sci; 2005; 47(4):251-7. PubMed ID: 16255396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
    Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
    Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Levodopa and cognitive disorders in Parkinson's disease].
    Leiva-Santana C; Alvarez-Saúco M
    Rev Neurol; 2006 Jul 16-31; 43(2):95-100. PubMed ID: 16838257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
    de la Fuente-Fernández R; Schulzer M; Mak E; Calne DB; Stoessl AJ
    Brain; 2004 Apr; 127(Pt 4):888-99. PubMed ID: 14960500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on the treatment of Parkinson's disease.
    Wirz D
    Conn Med; 1985 Oct; 49(10):633-7. PubMed ID: 3933903
    [No Abstract]   [Full Text] [Related]  

  • 10. [Contribution to the biochemical treatment of the Parkinson's disease (author's transl)].
    Calatayud Maldonado V
    Rev Esp Otoneurooftalmol Neurocir; 1978; 36(204):33-41. PubMed ID: 741072
    [No Abstract]   [Full Text] [Related]  

  • 11. [Drug therapy in Parkinson's disease].
    van Hilten JJ; Roos RA
    Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The neurochemistry of therapeutics: levodopa pharmacodynamics in Parkinson's disease.
    Frey KA
    Ann Neurol; 2001 Mar; 49(3):285-7. PubMed ID: 11261500
    [No Abstract]   [Full Text] [Related]  

  • 13. Nosography of Parkinson's disease.
    Gerstenbrand F; Ransmayr G
    J Neural Transm Suppl; 1986; 22():119-28. PubMed ID: 3465866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levodopa therapeutics for Parkinson's disease: new developments.
    LeWitt PA
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S31-4. PubMed ID: 19131040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Initial management and adaptation of Parkinson's disease treatment].
    Gérard JM
    Rev Med Brux; 2008 Sep; 29(4):229-31. PubMed ID: 18949969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
    Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
    Kostrzewa RM; Kostrzewa JP; Brus R
    Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levodopa for Parkinson's disease.
    Gérard JM; Elosegi JA
    N Engl J Med; 2009 Feb; 360(9):936; author reply 936. PubMed ID: 19256032
    [No Abstract]   [Full Text] [Related]  

  • 19. Update on the management of Parkinson's disease.
    Standaert DG; Stern MB
    Med Clin North Am; 1993 Jan; 77(1):169-83. PubMed ID: 8093493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current approaches in the treatment of Parkinson disease].
    Caraceni T; Geminiani G; Tamma F
    Recenti Prog Med; 1989 Dec; 80(12):686-91. PubMed ID: 2576471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.